Skip to search formSkip to main contentSkip to account menu

MKC-1

An orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites… 
National Institutes of Health

Related topics

Related topics

2 relations
Microtubule ProcessR440

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Raf Kinase Inhibitor Protein (RKIP) Blocks Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Breast and Prostate Cancer
Raf kinase inhibitor protein (RKIP) is a member of the phosphatidylethanolamine-binding-protein (PEBP) family that modulates the… 
Review
2012
Review
2012
mTOR inhibitors in breast cancer: a systematic review.
2012
2012
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design
SummaryBackground MKC-1 is an oral cell-cycle inhibitor with broad antitumor activity in preclinical models. Clinical studies… 
2012
2012
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer
SummaryBackground MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin… 
2009
2009
Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer.
5577 Background: MKC-1 is a novel oral cell cycle inhibitor with preclinical activity in xenograft models of human ovarian and… 
2009
2009
Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).
e19005 Background: MKC-1 is a novel oral cell cycle inhibitor with preclinical activity against NSCLC cell lines including multi… 
2008
2008
A phase II study of oral MKC-1 for metastatic breast cancer (MBC)
1046 Background: MKC-1 is a novel oral cell cycle inhibitor with in vitro and in vivo activity against many tumor cell lines… 
2007
2007
Phase 2 study of MKC-1 in patients (pts) with metastatic breast cancer (MBC) who have failed prior therapy with an anthracycline (A) and taxane (T)
11508 Background: MKC-1 (previously Ro 31–7453) is a novel cell cycle inhibitor with significant in vitro and in vivo activity… 
2006
2006
MKC-1 Is a Novel Agent That Induces Cell Cycle Arrest and Disrupts Multiple Survival Pathways in Hematologic Cancers.
MKC-1 is a novel, orally active cell cycle inhibitor with in vitro and in vivo activity against a wide range of human solid tumor… 
1999
1999
In vitro characteristics of early epidermal progenitors isolated from keratin 14 (K14)‐deficient mice: Insights into the role of keratin 17 in mouse keratinocytes
Keratin 14 (K14) is believed to play a pivotal role in the maintenance of epidermal cell shape and contributing to their… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)